Abstract

COVID-19 pandemic has caused various global changes. Since the World Health Organization (WHO) announced the end of the Covid 19 health emergency on May 11 2023, this does not mean that COVID-19 has disappeared. COVID-19 remains a global health threat. There is no clear limit regarding when COVID-19 will end. The emergence of new variants and waves of infection remain to be watched. Even now, long Covid symptoms can be experienced by people who have had Covid-19 and have been declared cured. Various prevention and treatment efforts are still being carried out to reduce the risk of morbidity and death, especially in comorbid sufferers. This study was a literature review which collected articles from Google Scholar databases published from 2012 until 2020. Fourteen articles were collected, but only six articles were discussed because of their relevant topics. There is no specific treatment for COVID-19 to date. The very high mortality rate in severe acute respiratory syndrome (SARS) Coronavirus (CoV)-2-related (SARS-CoV-2) patients is caused by acute respiratory distress syndrome (ARDS). Cytokine storms cause high levels of inflammation so oxygen levels in the tissues are greatly decreased resulting in ARDS. Existing treatments have not given optimal results. Hyperbaric oxygen is expected to be an adjunctive therapy in preventing and reducing deaths from ARDS.

There is no Figure or data content available for this article

References

• 1. Ragab D, Eldin HS, Taeimah M KR and SR. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020;
• 2. Sinha P, Matthay MA CC. Is a “Cytokine Storm” Relevant to COVID- 19? JAMA Intern Med. 2020;
• 3. Cherian SV, Kumar A, Akasapu K, Ashton RW AM and MA. Salvage therapies for refractory hypoxemia in ARDS. Respir Med. 2018;141:150–8.
• 4. Harch PG, Andrews SR, Fogarty EF, Lucarini J and VMK. Case control study: hyperbaric oxygen treatment of mild traumatic brain injury persistent post-concussion syndrome and post-traumatic stress disorder. Med Gas Res. 2017;7(3):156–74.
• 5. Jain KK. Basic aspect, Physical, Physiological, and Biochemical Aspects of Hyperbaric Oxygenation. 2017. 3–21 p.
• 6. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ S, HA, Schlaak M, Kochanek M, Böll B and von B-BM. Cytokine release syndrome. J Immunother Cancer. 2018;6:56.
• 7. Wang H, Shi Y, Song J, Qi J, Lu G, Yan J, et al. Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. Cell [Internet]. 2016;164(1):258–68. Available from: https://www.sciencedirect.com/science/article/pii/S0092867415017080
• 8. Xu J, Doyon-Plourde P, Tunis M, Quach C. Effect of early measles vaccination on long-term protection: A systematic review. Vaccine. 2021 May;39(22):2929–37.
• 9. Coperchini F, Chiovato L, Croce L, Magri F RM. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine receptor system. Cytokine Growth Factor Rev. 2020;53:25–32.
• 10. Nassar M.S., Bakhrebah M.A., Meo S.A., Alsuabeyl M.S. ZW. No TitleMiddle east respiratory syndrome coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci. 2018;
• 11. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I KS. Cytokine storm in COVID-19: pathogenesis and overviewof anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;39:2085–94.
• 12. Lu QC, Zhang TY, Bundhun PK, Chen C. One “misunderstood” health issue: demonstrating and communicating the safety of influenza a vaccination in pregnancy: a systematic review and meta-analysis. BMC Public Health. 2021 Apr;21(1):703.
• 13. Afsar B, Kanbay M and AR. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis. Med Hypotheses. 2020;143:109857.
• 14. Pacha O SM& ES. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020;20:345–6.
• 15. Bhandari R, Khanna G, Kuhad A. Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic. Eur J Pharmacol. 2021 Jan;890:173643.
• 16. Han SH and Mallampalli RK. The acute respiratory distress syndrome: from mechanism to translation. J Immunol. 2015;194(3):855–60.
• 17. Krähling V, Erbar S, Kupke A, Nogueira SS, Walzer KC, Berger H, et al. Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection. Mol Ther [Internet]. 2023;31(2):374–86. Available from: https://www.sciencedirect.com/science/article/pii/S1525001622006232
• 18. Tignanelli CJ, Hemmila MR, Rogers M RK. Nationwide cohort study of independent risk factors for acute respiratory distress syndrome after trauma. Trauma Surg Acute Care Open. 2019;4:e000249.
• 19. Cherian SV, Kumar A, Akasapu K, Ashton RW, Aparnath M and MA. Salvage therapies for refractory hypoxemia in ARDS. Respir Med. 2018;141:150–8.
• 20. Zarreen Simnani F, Singh D, Patel P, Choudhury A, Sinha A, Nandi A, et al. Nanocarrier vaccine therapeutics for global infectious and chronic diseases. Mater Today [Internet]. 2023; Available from: https://www.sciencedirect.com/science/article/pii/S1369702123001128
• 21. Yang Y, Yu X, Zhang Y, Ding G, Zhu C, Huang S, Jia S ZA. Hypoxiainducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury. Clin Sci. 2018;132(7):825–38.
• 22. Kubaichuk K KT. Involvement of E3 Ligases and Deubiquitinases in the Control of HIF-? Subunit Abundance. Cells. 2019;8(6):598.
• 23. Park JK, Lee EB, Shin K, Sung YK, Kim TH, Kwon SR, et al. COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology. J Korean Med Sci. 2021 Mar;36(12):e95.
• 24. Qian C, Yun Z, Yao Y, Cao M, Liu Q, Hu S, Zhang S LD. Heterogeneous macrophages: Supersensors of exogenous inducing factors. J Immunol. 2019;90:e12768.
• 25. Ke X, Chen C, Song Y, Cai Q, Li J, Tang Y, Han X, Qu W, Chen A WH, Xu G LD. Hypoxia modifies the polarization of macrophages and their inflammatory microenvironment, and inhibits malignant behavior in cancer cells. Oncol Lett. 2019;5871–8.
• 26. Wang Y, Smith W, Hao D, He B KL. M1 and M2 macrophage polarization and potentially therapeutic naturally occurring compounds. Int Immunopharmacol. 2019;70:459–66.
• 27. Kong X GJ. Macrophage polarization: a key event in the secondary phase of acute spinal cord injury. J Cell Mol Med. 2017;21(5):941–54.
• 28. Orecchioni M, Ghosheh Y PA and LK. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS–) vs. Alternatively Activated Macrophages. Front Immunol. 2019;
• 29. Lisi L , Ciotti GMP, Braun D, Kalinin S, Currò D , Russo CD, Coli A M, A, Anile C, D Feinstein L NP. Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in humanglioblastoma and the surrounding normal parenchyma. 2017;645:106–12.
• 30. Chen X, Tang J, Shuai W, Meng J FJ& HZ. Macrophage polarization and its role in the pathogenesis of acute lung injury/acute respiratory distress syndrome. Inflamm Res. 2020;
• 31. Parisi L, Gini L, Baci D, Tremolati M, Fanuli M, Bassani B, Farronato G B, A and ML. Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders? J Immunol Res. 2018;2018:8917804.
• 32. Gu B, Kaneko T, Zaw SYM, Sone PP, Murano H, Sueyama Y ZZ, T O. Macrophage populations show an M1-to-M2 transition in an experimental model of coronal pulp tissue engineering with mesenchymal stem cells. Int Endod J. 2018;52(4):504–14.
• 33. Malyshev I and Malyshev Y. No TitleCurrent Concept and Update of the Macrophage Plasticity Concept: Intracellular Mechanisms of Reprogramming and M3 Macrophage “Switch” Phenotype. Biomed Res Int. 2015;2015:341308.
• 34. Sun YY, Li XF, Meng XM, Huang C, Zhang L & LJ. Macrophage Phenotype in Liver Injury and Repair. Found Scand J Immunol. 2016;
• 35. Lu HL, Huang XY; Luo YF, Tan WP, Chen PF GY. Activation of M1 macrophages plays a critical role in the initiation of acute lung injury. Biosci Rep. 2018;38(2):BSR20171555.
• 36. Cavezzi A, Troiani E and CS. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin Pr. 2020;10(2):1271.
• 37. Eggleton P, Bishop AJ SG. Safety and effiTcacy of hyperbaric oxygen therapy in chronic wound management: current evidence. Chronic Wound Care Manag Res. 2015;2:81–93.
• 38. Harnanik T, Soeroso J SM. Hyperbaric Oxygen Effect on Switching Phenotype M1-M2 Macrophage Expression in Antigen and Collagen-Induced Arthriti. Int Med J Res. 2019;26:6.
• 39. Heyboer M, Sharma D, Santiago W MCN. Affiliations Hyperbaric Oxygen Therapy: Side Effects Defined and Quantified. Adv Wound Care (New Rochelle). 2017;6(6):210–24.
• 40. Iglesias, Penas C, Barral-Cagiao L PE& CJ. No TitleA Bio-inspired Hypoxia sensor using HIF1a-Oxygen-Dependent Degradation Domainpablo. Sci Rep. 2019;9:7117.
• 41. Strowitzki MJ CE and TC. Protein Hydroxylation by Hypoxia-Inducible Factor(HIF) Hydroxylases: Unique or Ubiquitous? Cells. 2019;8:384.
• 42. Predonzani A. Spotlights on immunological effects of reactive nitrogen species: When inflammation says nitric oxide. World J Exp Med. 2015;5(2):64.
• 43. Greer SN, Metcalf JL, Wang Y OM. The updated biology of hypoxiainducible factor. EMBO J. 2012;31(11):2448–60.
• 44. Wilson GK, Tennant DA MJ. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: Current understanding and future directions. J Hepatol. 2014;61(6):1397–406.
• 45. Semenza GL. Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33(4):207–14.
• 46. Hua S DT. Hypoxia-Inducible Factor (HIF) as a target for novel therapies in rheumatoid arthritis. Front Pharmacol. 2016;7:1–9.
• 47. Marchetti M. COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure. Ann Hematol. 2020;24:1–7.
• 48. Rath M, Müller I, Kropf P, Closs EI MM. Metabolism via arginase or nitric oxide synthase: Two competing arginine pathways in macrophages. Front Immunol. 2014;5:1–1.
• 49. Prossera G, Brandenburgb J, Reilingb N, Barry CE, Wilkinsonc RJ W, KA. The bacillary and macrophage response to hypoxia in tuberculosis and theconsequences for T cell antigen recognition. Microbes Infect. 2017;19:177e192.
• 50. Zhao C, Mirando AC, Sove ?RJ, Medeiros TX, Annex BH PA. A mechanistic integrative computational model of macrophage polarization?: Implications in human pathophysiology. PLoS Comput Bio. 2019;15(11):e1007468.
• 51. Zhao C, Mirando AC, Sove ?RJ, Medeiros TX, Annex BH, Popel AS. A mechanistic integrative computational model of macrophage polarization : Implications in human pathophysiology. PLoS Comput Bio . 2019: 15(11):e1007468
• 52. Buras JA, et al. Hyperbaric oxygen therapy for acute respiratory distress syndrome: a clinical trial. J Crit Care. 2019; 53:120-125.
• 53. Smith G, et al. The combined effects of corticosteroids and hyperbaric oxygen therapy in ARDS: A randomized controlled trial. Intensive Care Med. 2020; 46(7):1345-1352.
• 54. Xu X, et al. Tocilizumab treatment in severe COVID-19 patients with cytokine storm: a randomized clinical trial. Lancet Respir Med. 2021; 9(10):950-958.

How to Cite This

Article Metrics

Download Statistics

Downloads

Download data is not yet available.

Other Statistics

Copyright and Permissions

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

• BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability